NCT00866047 · OUTCOME

B Symptom Resolution

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percent of participants
Interval / dispersion: 95% Confidence Interval
Time frame: up to 12 months

What was measured

Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.

Analysis population: Participants with B symptoms at baseline

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Brentuximab Vedotin	17

Reported measurements

Source class 1

Values in percent of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Brentuximab Vedotin	82	Not reported	56.6	96.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
56.6
upper Limit
96.2
value
82

denoms

counts
group Id
OG000
value
17
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
id
OG000
title
Brentuximab Vedotin

param Type

NUMBER

population Description

Participants with B symptoms at baseline

reporting Status

POSTED

time Frame

up to 12 months

title

B Symptom Resolution

type

OTHER_PRE_SPECIFIED

unit Of Measure

percent of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice